Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy
about
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTLMelanoma-associated antigen synthesized in vitro for active specific immunotherapy.Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.Vaccinia virus vectors: new strategies for producing recombinant vaccines.A molecular model for the tumour-associated antigen, p97, suggests a Zn-binding function.Possibilities for active immunotherapy of human cancer.Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.The next wave of recombinant and synthetic anticancer vaccines.Epitope- and antigen-specific cancer vaccines.Genetically engineered poxviruses for recombinant gene expression, vaccination, and safetyHuman papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.Vaccinia virus: a tool for research and vaccine development.Prospects for the treatment of B cell tumors using idiotypic vaccination.Anti-idiotypic tumor vaccines.Animal models of human-derived cancer vaccines.Tumor antigens known to be immunogenic in man.Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic targetOn the role of costimulation in tumor immunity.Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice.Immunotherapeutic strategies for cancer using poxvirus vectors.Immunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines.Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
P2860
Q24684276-A5EFB266-92EB-4A26-8ABD-1C5F59B7323FQ33188234-DDEA4A93-B804-4D62-859C-3981FBBE620DQ33920696-2430C563-1422-4811-BDA5-4F1173D22586Q34211635-93547955-85AC-424F-B614-92607E3F0B19Q34474237-E8A1A495-190D-48F6-8C08-644F6A300BC4Q35326752-97732CEB-3E4C-4E0C-B5C1-C58A99F65F82Q35946213-543122DE-589C-4C66-9F17-C24C9B009C70Q35950374-7AF80CD6-A86A-4F38-AC84-E8E6686CF076Q36088999-85E309F8-AF05-4784-A9B4-F15AA562E087Q36091993-598DB057-C349-48A4-BDD4-0D1FEAFA5AD7Q36470715-BC95F54D-2C67-4988-89F7-5DFBD983453DQ36470749-A13A6B23-F9F4-4ACF-807B-0DE22C67243BQ36930069-D8DD5F11-90F9-4BB7-88AC-74652EA3987FQ37249251-C61F33B1-D74D-47C0-B9CE-5AD2BF81B1F7Q37360322-1C84C5C4-794F-4B26-8AB1-B1DB001CD76CQ37755852-FEE92345-F072-4BBB-B4E8-C53D0FE0E3D7Q38246920-657D6B76-6505-442A-87F3-274C719A6993Q38246921-188AD48C-9C35-4B11-B1C5-48AD1DC9F94EQ40378570-3B8B121C-EAEC-4A99-B345-0026F8040131Q40844527-CE1E376C-C7D5-47E6-A690-C3E15E5A4990Q40865882-E7D63072-67EF-4007-A40B-DCC70CD4FD90Q41534263-3EC57842-A885-4930-BC9D-BAE31B8EED3AQ42816298-69F085B2-9DBB-432C-B042-A9B7BF8FA3E9Q43754300-4D215640-1112-43A4-8DC1-8B92AF9BBE20Q45868793-A7E2A1BE-CAA1-4A38-A8F5-D24B8BB3CE10Q45884692-9858331D-CC65-44E4-B245-D844898E895D
P2860
Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy
description
1988 nî lūn-bûn
@nan
1988 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@ast
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@en
Recombinant vaccinia virus vac ...... p97 for use in immunotherapy.
@nl
type
label
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@ast
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@en
Recombinant vaccinia virus vac ...... p97 for use in immunotherapy.
@nl
prefLabel
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@ast
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@en
Recombinant vaccinia virus vac ...... p97 for use in immunotherapy.
@nl
P2093
P2860
P356
P1476
Recombinant vaccinia virus vac ...... n p97 for use in immunotherapy
@en
P2093
Hellström I
Hellström KE
Plowman GD
Stevenson US
P2860
P304
P356
10.1073/PNAS.85.4.1052
P407
P577
1988-02-01T00:00:00Z